Brochure: Fast and simple plasma protein binding studies
Posted: 17 February 2021 | Merck | No comments yet
Supel™ BioSPME 96-Pin Devices vastly outperform current sample preparation techniques for plasma protein binding studies and free fraction analyses.
Based on solid phase microextraction technology, the Supel™ BioSPME 96-Pin Devices are 3x faster than rapid equilibrium dialysis workflows at similar levels of data accuracy and precision, they remove all phospholipids, deliver reproducible results across batches and each 96-sample device, and allow both manual and automated workflows.
An application note features the results of a detailed comparison with the rapid equilibrium dialysis technique.
Related content from this organisation
- Moderna-Merck & Co cancer vaccine with Keytruda shows late-stage promise
- Raman-based PAT tool could advance continuous vaccine manufacturing
- Merck acquires JSR Life Sciences chromatography business
- MSD acquisition to accelerate first-in-class COPD drug
- Next drug patent cliff to challenge Big Pharma strategy
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, QA/QC, Regulation & Legislation, Research & Development (R&D)
